Related references
Note: Only part of the references are listed.Society Guidelines 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
Glen J. Pearson et al.
CANADIAN JOURNAL OF CARDIOLOGY (2021)
Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence
Peter P. Toth et al.
DIABETES OBESITY & METABOLISM (2020)
Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors
Benjamin Miao et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
PCV32 ECONOMIC BURDEN OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND SPECIFIC EVENTS IN ONTARIO, CANADA
R. Rogoza et al.
VALUE IN HEALTH (2020)
The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of real world practice in people with diabetes
Manju Bengaluru Jayanna et al.
DIABETES OBESITY & METABOLISM (2019)
Treatment and Low-Density Lipoprotein Cholesterol Management in Patients Diagnosed With Clinical Atherosclerotic Cardiovascular Disease in Alberta
Guanmin Chen et al.
CANADIAN JOURNAL OF CARDIOLOGY (2019)
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Paul D. Rosenblit
CURRENT DIABETES REPORTS (2019)
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
Francois Mach et al.
ATHEROSCLEROSIS (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Interpreting the Findings From the Recent PCSK9 Monoclonal Antibody Cardiovascular Outcomes Trials
Nathan D. Wong et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2019)
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
Konstantinos C. Koskinas et al.
EUROPEAN HEART JOURNAL (2018)
Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review
Dasha Cherepanov et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long term health outcomes in patients with a history of myocardial infarction: A population based cohort study
Navdeep Tangri et al.
PLOS ONE (2017)
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome
Connie N. Hess et al.
AMERICAN HEART JOURNAL (2017)
Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact
Jack V. Tu et al.
CANADIAN JOURNAL OF CARDIOLOGY (2017)
Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes
Lisa Elliott et al.
DIABETES THERAPY (2016)
Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes
Lisa Elliott et al.
DIABETES THERAPY (2016)
Global Overview of the Epidemiology of Atherosclerotic Cardiovascular Disease
Simon Barquera et al.
ARCHIVES OF MEDICAL RESEARCH (2015)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
Jordan Fulcher et al.
LANCET (2015)
The CANHEART health index: a tool for monitoring the cardiovascular health of the Canadian population
Laura C. Maclagan et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2014)
2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
Todd J. Anderson et al.
CANADIAN JOURNAL OF CARDIOLOGY (2013)
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
Matthew T. Roe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Jessica L. Mega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Pierluigi Tricoci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
John H. Alexander et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors
Douglas S. Lee et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization
Manesh R. Patel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
